SYKStryker Corporation

Healthcare

$277.28-26% 1Y

$277.28

$269.8652 weeks$386.41

Is the price fair?

Fair

Neither cheap nor expensive: growth expectations in line with delivery and in its normal P/E range.

3 neutral

What the price assumes~+9% a year

Priced for ~9% a year FCF growth. Roughly in line with its three-year revenue growth of 10% a year.

Vs its own P/E rangemid-range for this companyderived

In its normal range: P/E 28.7 vs a 39.6 median over 41 quarters (−27% vs median).

Vs sector (EV/EBIT)23.9×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What SYK's price assumes

Stryker Corporation trades at 28.7× earnings against 26.2× for the median Medical Devices name, more expensive than its own group.

28.7

Trailing P/E · Medical Devices median 26.2 · 1.10× the median: the market pays up for this one

Price / sales: 4.65
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 3.9%
Free cash flow yield · Medical Devices median 4.5%
Growth the price implies: +8.9%
Growth the price implies · The price pays for +8.9% free cash flow growth a year for a decade; the business has delivered +25% a year over the last three.

Details›

Price / booktoday's price, trailing year to Jun 30, 2026: 5.01
EV / EBITtoday's price, trailing year to Jun 30, 2026: 23.9
EV / salestoday's price, trailing year to Jun 30, 2026: 5.11
Healthcare median P/E509 names: 26.2
Medical Devices median P/E64 names: 26.2
Free cash flow, trailing twelve months: $4.70B
Market capitalisation: $120.3B
3-year revenue growth: +9.9%
3-year free cash flow growth: +25%

What the market has paid for these earnings: 41 quarters of its own multiple × $9.65 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$271.89
Its own P/E history, median	$382.06
Its own P/E history, upper quartile	$470.41
52-week range	$269.86 – $386.41
Today	$277.28

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

On our screens:Quality compounders Low-volatility growth stocks Quality at a reasonable price

Medical Devices

Ranks #6 of 51 by RyuScore